PerkinElmer, Inc.
About PerkinElmer, Inc.
745 articles with PerkinElmer, Inc.
-
PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis
10/18/2021
PerkinElmer, Inc. (NYSE: PKI) and Honeycomb Biotechnologies, Inc., announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis.
-
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
10/7/2021
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.
-
PerkinElmer’s Horizon Discovery CHOSOURCE™ Platform Expanding To Include CHO-K1 ADCC+ Expression Cell Line for Development of Therapeutic Antibodies in Oncology, Infectious Disease and Autoimmune Conditions
10/6/2021
PerkinElmer Inc today announced that its Horizon Discovery CHOSOURCE™ platform is expanding to include a new expression cell line, CHO-K1 ADCC+ .
-
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
9/17/2021
PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.
-
PerkinElmer to Present at 2021 Baird Global Healthcare Conference
8/24/2021
PerkinElmer, Inc, today announced that the Company will present at the virtual Baird Global Healthcare Conference on Tuesday, September 14, 2021 at 10:50 a.m. ET.
-
PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins
8/19/2021
PerkinElmer, Inc today announced the launch of its MaxSignal® Mycotoxin Automation Bundle .
-
PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits
7/28/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced four new ready-to-use AlphaLISA® KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers.
-
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
7/26/2021
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.
-
PerkinElmer Announces Financial Results for the Second Quarter of 2021
7/26/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021.
-
It's been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
-
Ampersand Completes Sale of Portfolio Company Nexcelom Bioscience to PerkinElmer
6/25/2021
Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.
-
PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021
6/24/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced ahead of this morning’s Virtual Investor and Analyst Day that it anticipates exceeding its previously announced financial guidance for the second quarter ending July 4, 2021, driven by broad-based momentum across both COVID and non-COVID businesses.
-
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
6/22/2021
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
-
PerkinElmer Supports JUMP-CP Consortium Creating World’s Largest, Public Cell Painting Dataset
6/7/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is providing its PhenoVue™ Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium
-
Welsh Lighthouse Laboratory Extends Contract with PerkinElmer for its COVID-19 Solutions
5/27/2021
Company’s RT-PCR kits and workflow solutions will continue to safeguard capacity for NHS Test and Trace laboratory
-
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
5/17/2021
PerkinElmer, Inc. and Immunodiagnostic Systems Holdings PLC are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million.
-
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
-
PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience
5/12/2021
PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.
-
PerkinElmer Announces Financial Results for the First Quarter of 2021
5/4/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 4, 2021.
-
PerkinElmer to Host Virtual Investor and Analyst Day
5/4/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to 12:00 p.m. ET.